1. |
Cabrera T, Maleno I, Collado A, et al. Analysis of HLA class I alterations in tumors:choosing a strategy based on known patternsof underlying molecular mechanisms[J]. Tissue Antigens, 2007, 69(Suppl 1):264-268.
|
2. |
Nagorsen D, Thiel E. HLA typing demands for peptide-based anti-cancer vaccine[J]. Cancer Immunol Immunother, 2008, 57(12):1903-1910.
|
3. |
-microglobulin (beta 2m) with mouse class I major histocompati-bility antigens and its ability to support peptide binding. A comp-arison of human and mouse beta 2m[J]. Eur J Immunol, 1995, 25(6):1609-1616.
|
4. |
Marincola FM, Jaffee EM, Hicklin DJ, et al. Escape of human solid tumors from T-cell recognition:molecular mechanisms and functional significance[J]. Adv Immunol, 2000, 74:181-273.
|
5. |
Tangri S, Ishioka GY, Huang X, et al. Structural features of peptideanalogs of human histocompatibility leukocyte antigen class I epitopes that are more potent and immunogenic than wild-typepeptide[J]. J Exp Med, 2001, 194(6):833-846.
|
6. |
Garrido F, Cabrera T, Concha A, et al. Natural history of HLA expression during tumour development[J]. Immunol Today, 1993, 14(10):491-499.
|
7. |
Garrido F, Ruiz-Cabello F, Cabrera T, et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours[J]. Immunol Today, 1997, 18(2):89-95.
|
8. |
Hicklin DJ, Marincola FM, Ferrone S. HLA class I antigen downregulation in human cancers:T-cell immunotherapy revives an old story[J]. Mol Med Today, 1999, 5(4):178-186.
|
9. |
Pedersen LO, Stryhn A, Holter TL, et al. The interaction of beta.
|
10. |
Cabrera T, Angustias Fernandez M, Sierra A, et al. High frequ-ency of altered HLA class I phenotypes in invasive breast carcinomas[J]. Hum Immunol, 1996, 50(2):127-134.
|
11. |
Tsukahara T, Kawaguchi S, Torigoe T, et al. Prognostic significance of HLA class I expression in osteosarcoma defined by anti-panHLA class I monoclonal antibody, EMR8-5[J]. Cancer Sci, 2006, 97(12):1374-1380.
|
12. |
Qifeng S, Bo C, Xingtao J, et al. Methylation of the promoter of human leukocyte antigen class I in human esophageal squamous cell carcinoma and its histopathological characteristics[J]. J Thorac Cardiovasc Surg, 2011, 141(3):808-814.
|
13. |
Kikuchi E, Yamazaki K, Torigoe T, et al. HLA class I antigen expression is associated with a favorable prognosis in early stage non-small cell lung cancer[J]. Cancer Sci, 2007, 98(9):1424-1430.
|
14. |
Kitamura H, Honma I, Torigoe T, et al. Down-regulation of HLA class I antigen is an independent prognostic factor for clear cell renal cell carcinoma[J]. J Urol, 2007, 177(4):1269-1272.
|
15. |
Ishigami S, Natsugoe S, Nakajo A, et al. HLA-class I expression in gastric cancer[J]. J Surg Oncol, 2008, 97(7):605-608.
|
16. |
Campoli M, Ferrone S. HLA antigen changes in malignant cells:epigenetic mechanisms and biologic significance[J]. Oncogene, 2008, 27(45):5869-5885.
|
17. |
de Kruijf EM, Sajet A, van Nes JG, et al. HLA-E and HLA-G expression in classical HLA class I-negative tumors is of prognosticvalue for clinical outcome of early breast cancer patients[J]. J Immunol, 2010, 185(12):7452-7459.
|
18. |
Boomsma MF, Garssen B, Slot E, et al. Breast cancer surgery-induced immunomodulation[J]. J Surg Oncol, 2010, 102(6):640-648.
|
19. |
de Kruijf EM, van Nes JG, Sajet A, et al. The predictive value of HLA class I tumor cell expression and presence of intratumoral Tregs for chemotherapy in patients with early breast cancer[J]. Clin Cancer Res, 2010, 16(4):1272-1280.
|
20. |
Lavado-Valenzuela R, Benavides M, Carabantes F, et al. MHC class I chain-related gene A transmembrane polymorphism in Spanish women with breast cancer[J]. Tissue Antigens, 2009, 74(1):46-49.
|
21. |
Torigoe T, Asanuma E, Tamura Y, et al. Establishment of a mono-clonal anti-pan HLA class I antibody suitable for immunostainingof formalin-fixed tissue:unusually high frequency of down-regulation in breast cancer tissues[J]. Pathol Int, 2012, 62(5):303-308.
|
22. |
Cordon-Cardo C, Fuks Z, Drobnjak M, et al. Expression of HLA-A, B, C antigens on primary and metastatic tumor cell populations of human carcinomas[J]. Cancer Res, 1991, 51(23 Pt 1):6372-6380.
|
23. |
Madjd Z, Spendlove I, Pinder SE, et al. Total loss of MHC class I is an independent indicator of good prognosis in breast cancer[J]. Int J Cancer, 2005, 117(2):248-255.
|
24. |
Sato N, Hirohashi Y, Tsukahara T, et al. Molecular pathological approaches to human tumor immunology[J]. Pathology International, 2009, 59(4):205-217.
|
25. |
Mizukami Y, Kono K, Maruyama T, et al. Downregulation of HLA Class I molecules in the tumour is associated with a poor prognosis in patients with oesophageal squamous cell carcinoma[J]. Br J Cancer, 2008, 99(9):1462-1467.
|
26. |
Pistillo MP, Nicolò G, Salvi S, et al. Biochemical analysis of HLA class I subunits expression in breast cancer tissues[J]. Hum Immunol, 2000, 61(4):397-407.
|
27. |
Zia A, Schildberg FW, Funke I. MHC class I negative phenotype of disseminated tumor cells in bone marrow is associated with poor survival in R0M0 breast cancer patients[J]. Int J Cancer, 2001, 93(4):566-570.
|